HIV pills and new lung drugs keep GSK on track in Q3

LONDON (Reuters) - GlaxoSmithKline grew sales 4 percent in the third quarter, helped by demand for new products, keeping it on track to deliver on full-year financial targets as new Chief Executive Emma Walmsley refocuses the drugs pipeline.